Single-Dose Anti–PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses

Immunocytokines hold great potential as anticancer agents, as they use a specific antitumor antibody to deliver an immune-activating cytokine directly to the immunosuppressive tumor microenvironment (TME). We have developed a novel immunocytokine (KD033) composed of a fully human, high-affinity antiprogrammed death-ligand 1 (PD-L1) linked to the sushi-domain of the human IL-15/IL-15 receptor alpha (IL-15/IL-15Rα) complex. A murine PD-L1 cross-reactive KD033 surrogate (srKD033) and a nontargeting antibody (ntKD033) were also developed to investigate mechanism of action in murine tumor models. Efficacy analyses showed a robust antitumor effect of single-dose srKD033 in several diverse syngeneic murine tumor models. In a CT26 murine colon tumor model, single-dose srKD033 produced durable antitumor immunity as evidenced by resistance to subsequent tumor rechallenges. Mice responding to srKD033 treatment showed increased retention of PD-L1/IL-15 in the TME which likely facilitated prolonged IL-15–induced expansion of cytotoxic cells. Importantly, target-based PD-L1/IL-15 delivery via srKD033 was well-tolerated and induced significant antitumor activity in murine carcinoma models that are non- or minimally responsive to IL-15 or anti–PD-L1/PD-1 monotherapy.

[1]  M. Merad,et al.  PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer , 2020, Nature Cancer.

[2]  Kwok-Kin Wong,et al.  PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer , 2020, Nature Immunology.

[3]  Xiaozheng Xu,et al.  PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. , 2019, Immunity.

[4]  T. Okazaki,et al.  Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses , 2019, Science.

[5]  P. Kuppen,et al.  Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile , 2019, Cancer Immunology, Immunotherapy.

[6]  J. Schlom,et al.  Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy , 2019, Journal of Immunotherapy for Cancer.

[7]  J. Wolchok,et al.  Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  C. Szeto,et al.  The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex , 2018, Oncoimmunology.

[9]  O. Boyman,et al.  The role of cytokines in T‐cell memory in health and disease , 2018, Immunological reviews.

[10]  J. Wolchok,et al.  Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. , 2016, JAMA.

[11]  Jedd D. Wolchok,et al.  PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.

[12]  M. Atkins,et al.  High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014 , 2014, Journal of Immunotherapy for Cancer.

[13]  M. Sznol.  Blockade of the B7-H1/PD-1 Pathway as a Basis for Combination Anticancer Therapy , 2014, Cancer journal.

[14]  S. Lesage,et al.  Revisiting the Prominent Anti-Tumoral Potential of Pre-mNK Cells , 2013, Front. Immunol..

[15]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[16]  G. Freeman,et al.  PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. , 2013, The Journal of clinical investigation.

[17]  K. Margolin,et al.  Cytokines in Cancer Immunotherapy , 2011, Cancers.

[18]  Diana M. Mitchell,et al.  Distinct Roles for IL-2 and IL-15 in the Differentiation and Survival of CD8+ Effector and Memory T Cells , 2010, The Journal of Immunology.

[19]  J. D. Di Santo,et al.  IL-15 trans-presentation promotes human NK cell development and differentiation in vivo , 2009, The Journal of experimental medicine.

[20]  G. Pavlakis,et al.  Intracellular Interaction of Interleukin-15 with Its Receptor α during Production Leads to Mutual Stabilization and Increased Bioactivity* , 2008, Journal of Biological Chemistry.

[21]  A. Plet,et al.  Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. , 2006, The Journal of biological chemistry.

[22]  A. Mori,et al.  Increased Intratumor Vα24-Positive Natural Killer T Cells: A Prognostic Factor for Primary Colorectal Carcinomas , 2005, Clinical Cancer Research.

[23]  D. Raulet,et al.  Expression and function of NK cell receptors in CD8+ T cells. , 2001, Current opinion in immunology.

[24]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[25]  C. Figdor,et al.  Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. , 1998, Journal of immunology.

[26]  D. Cosman,et al.  IL‐15, a novel T cell growth factor that shares activities and receptor components with IL‐2 , 1995, Journal of leukocyte biology.

[27]  M. Klein,et al.  Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinant IgG1/IgG2 hybrid and point-mutated antibodies. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Morrison,et al.  The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region , 1991, The Journal of experimental medicine.

[29]  Keunchil Park,et al.  Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. , 2019, European journal of cancer.

[30]  T. Waldmann,et al.  Interleukin-15 biology and its therapeutic implications in cancer. , 2012, Trends in pharmacological sciences.

[31]  K. Sheppard,et al.  PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. , 2004, FEBS letters.